Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 9;8(19):31112-31118.
doi: 10.18632/oncotarget.16091.

The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review

Bum Jun Kim  1 , Jae Ho Jeong  2 , Jung Han Kim  1 , Hyeong Su Kim  1 , Hyun Joo Jang  3
Affiliations
Review

The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review

Bum Jun Kim et al. Oncotarget. .

Abstract

There has been debate as to whether targeted agents have beneficial effect when added to adjuvant chemotherapy for patient with colon cancer. We conducted this meta-analysis to investigate the role of targeted agents in the adjuvant treatment of colon cancer. We searched PubMed, MEDLINE, EMBASE, and the Cochrane Library databases. We included phase III trials with the data of disease-free survival (DFS) and adverse events (AEs) of adjuvant treatment with targeted agents. From 5 eligible studies, a total of 9,991 patients with resected colon cancer were included in the meta-analysis of hazard ratio (HR) for 3-year DFS and odds ratio (OR) for grade 3 or higher AEs. The addition of targeted agents showed no improvement of 3-year DFS, compared to standard adjuvant chemotherapy alone (HR = 1.04 [95% confidence interval (CI), 0.96-1.13], P = 0.31). In the subgroup analysis according to the type of targeted agents, neither bevacizumab (HR = 1.03 [95% CI, 0.88-1.21], P = 0.72) nor cetuximab (HR = 1.11 [95% CI, 0.94-1.31], P = 0.22) was associated with improvement of DFS. Moreover, targeted agents significantly increased grade 3 or higher AEs (OR = 1.73 [95% CI, 1.21-2.46], P = 0.003) and treatment-related death (OR = 2.15 [95% CI, 1.16-3.99], P = 0.02). In conclusion, this meta-analysis demonstrates that the addition of targeted agents to standard adjuvant chemotherapy results in no improvement of DFS with increased severe AEs and treatment-related death in patients with resected colon cancer.

Keywords: adjuvant treatment; bevacizumab; cetuximab; colon cancer; targeted agent.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

All authors have declared no competing interest.

Figures

Figure 1
Figure 1. Flow diagram of search process
Figure 2
Figure 2
Forest plots of hazard ratios comparing 3-year disease-free survival among all studies (A). Subgroup analysis according to the type of targeted agents; bevacizumab (B) and cetuximab (C).
Figure 3
Figure 3
Forest plots of odds ratios comparing the incidence of grade 3 or higher adverse events (A) and treatment-related death (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86. - PubMed
    1. Oh CM, Won YJ, Jung KW, Kong HJ, Cho H, Lee JK, Lee DH, Lee KH. Community of Population-Based Regional Cancer Registries. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013. Cancer Res Treat. 2016;48:436–50. - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
    1. Quasar Collaborative Group. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9. - PubMed
    1. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ, Spurr CL, Nikolay Dimitrov N, Romond EH, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11:1879–87. - PubMed

MeSH terms

LinkOut - more resources